WHO ICTRP trial
Study of safety and efficacy of Venetoclax in combination with Vidaza…
CTIS2024-514878-53-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-514878-53-00 |
|---|---|
| Public title | Study of safety and efficacy of Venetoclax in combination with Vidaza (Azacitidine) in higher-risk Chronic Myelomonocytic Leukemia (CMML) |
| Scientific title | AVENHIR trial: Phase II study with safety run-in of Azacitidine (AZA) combined with Venetoclax (VEN) in patients with higher-risk Chronic Myelomonocytic Leukemia (CMML) - AVENHIR |
| Primary sponsor | Groupe Francophone Des Myelodysplasies |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | France |
| Conditions | Newly diagnosed, HMA-naïve, higher-risk (HR, defined as CPSS risk intermediate-2 or high) CMML patients MedDRA version: 21.0Level: LLTClassification code: 10054350Term: Chronic myelomonocytic leukemia Class: 10029104;Therapeutic area… |
| Interventions | Product Name: Vidaza 25 mg/ml powder for suspension for injection, Product Code:PRD9244549, Pharmaceutical Form: SUSPENSION FOR INJECTION, Other descriptive name: , Strength: , Product Name: Venetoclax, Product Code:PRD2186235… |
| Registration date | Sep 9, 2024 |
| Target size | 44 |
| Secondary IDs | NCT05768711;2021-002007-35 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: